Ambit Biosciences' IPO

Ambit Biosciences raised a round of funding on May 16, 2013. Investors include Public.

Ambit Biosciences is a biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indicat…

Articles about Ambit Biosciences' IPO: